Business Wire

Gatik Raises $200 Million; Series D Led by QIA and KDT as Demand for Driverless Commercial Freight Accelerates

25.8.2026 15:00:00 CEST | Business Wire | Press release

Share

Gatik, the leader in autonomous trucking, today announced $200 million in financing as demand accelerates for driverless commercial freight across Fortune 50 retail, grocery and CPG supply chains. The Series D round was led by Qatar Investment Authority (QIA) and Koch Disruptive Technologies (KDT), with participation from Millennium Management, ARK Invest, Intact Private Capital and others.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825490075/en/

Gatik Announces Series D round

Gatik has built one of the most commercially advanced businesses in autonomous freight, with more than $600 million in contracted revenue, 85,000 fully driverless orders completed, and 99% on-time delivery across its operations. Its trucks move goods across high-frequency regional networks between distribution centers and stores, giving customers a reliable way to add capacity, improve service levels and keep products moving.

“This round, led by some of the world’s leading financial institutions, is a clear validation of Gatik’s commercial leadership in autonomous freight,” said Gautam Narang, CEO and Co-founder of Gatik. “We have built Gatik with real revenue, deep customer demand, and AI-driven autonomous technology proven every day in live supply chains. This round gives us the capital to scale with speed and discipline, serve the world’s largest companies, and define the future of autonomous freight.”

“Autonomous freight is transforming the global logistics industry, making it more efficient and reliable,” said Abdulla Al-Kuwari, Head of Industrials at QIA. “QIA is committed to supporting next-generation solutions providers like Gatik that are shaping the future of freight infrastructure.”

“We've long believed autonomous freight has the potential to improve the efficiency and reliability of supply chains,” said Byron Knight, President of Koch Disruptive Technologies.“What we're seeing today is autonomy moving beyond a promising technology into real-world commercial operations. Gatik has demonstrated a practical approach to that transition, and we look forward to supporting the company's continued growth.”

The latest financing round will help Gatik expand a model built around one of the most commercially compelling applications of autonomy: high-frequency regional routes that connect distribution centers and stores. These routes are time-sensitive, operationally complex and essential to keeping shelves stocked as customer expectations shift toward faster, more predictable access to everyday products.

“Autonomous freight is reaching an inflection point as AI and robotics converge to transform the transportation ecosystem,” said Cathie Wood, Founder, CEO, and CIO of ARK Invest. “The companies creating durable value will be those that translate breakthrough innovation into scalable commercial execution. Gatik has demonstrated that autonomous trucking is moving beyond experimentation into commercially viable operations with growing customer adoption. We believe the company is well positioned to help forge the future of freight transportation.”

“We are no longer debating the potential of autonomous trucking. This category will be led by the companies that have proven technology, rigorous safety standards and the commercial discipline to operate at scale,” said Justin Smith-Lorenzetti, Managing Director, Intact Private Capital.“Gatik has built that foundation over years of operating inside complex customer supply chains. We have tripled our commitment with this latest round, driven by the conviction that Gatik has the execution record, customer traction and technical maturity to be the leader in autonomous freight across North America.”

Gatik’s AI-first AV technology is purpose-built for autonomous trucking across highways and surface streets. Its driverless trucks use dynamic routes to help customers respond to changing demand, distribution center activity and pickup and drop-off needs across commercial networks.

With dozens of driverless trucks already operating today across North America, the company plans to expand to thousands in the years ahead.

OTHER KEY INVESTOR VOICES:

“We first invested in Gatik in 2021 because we believed in the potential for autonomous freight to transform how goods move,” said Celeste Dauner, Managing Director of Koch Disruptive Technologies. “Since then, we’ve watched Gatik execute successfully against that opportunity, building scale around a focused, highly practical application of autonomy. Our decision to invest again at this stage reflects our conviction in Gatik’s model and the significant opportunity ahead for autonomous freight.”

“Autonomous trucking should meaningfully lower the cost of transporting goods and reshape modern supply chains,” said Tasha Keeney, Director of Research for Autonomous Technology and Robotics and the Director of Investment Analysis at ARK Invest. “Gatik is leading this transformation by bringing driverless technology to regional networks and unlocking value for customers. We’re excited to support Gatik as it scales autonomous freight and helps define the next era of logistics.”

About Gatik

Gatik is in the business of autonomous freight. The company operates driverless trucks daily for Fortune 50 retailers, grocers and CPG companies, moving freight between distribution centers and stores across Texas, Arizona, Arkansas, and Canada. Gatik has a strong safety record across its operations and is powered by the Gatik Driver™, a scalable, interpretable AI system purpose-built to enable safe, consistent, and high-frequency freight movement. For more information, visit gatik.ai.

Forward-Looking Statements

This news release contains “forward-looking statements” that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or Gatik’s future financial or operating performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, revenue targets and trends we expect to affect our business. These statements often include words such as “contracted,” “anticipate,” “believe,” “may,” “can,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “target”, “will,” “estimate,” “predict,” “potential,” “continue,” “scheduled”. Forward-looking statements may also be made, verbally or in writing, by members of our Board or management team in connection with this news release.

These forward-looking statements are based on management’s current expectations and beliefs. These statements are neither promises nor guarantees, but involve and are subject to known and unknown risks, uncertainties and other important factors that may cause Gatik’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements, including Gatik’s ability to execute on its growth plans, any failure to comply with laws, rules, regulations or business practices that Gatik may become subject to as a result of any expansion of its business resulting from the financing, including Gatik’s ability to successfully execute on its growth strategies and operating plans, achieve its targeted annualized contracted revenue, continue to develop its existing customer base, design and deploy an expanded fleet of trucks on behalf of customers, and diversify and expand into the market for autonomous logistics solutions. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any forward-looking statement included in this press release speaks only as of the date of such statement. Except as required by law, Gatik disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise.

The securities described herein have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and were offered and sold in a transaction exempt from registration under the Securities Act. The securities may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

Gatik and the Gatik logo are trademarks of Gatik AI Inc. All other trademarks, service marks, and company names mentioned herein are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260825490075/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye